We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ORR

News List

Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma FirstWordPharma
December 14, 2021
Newswise — The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being..
ASH18: Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field fiercebiotech
January 02, 2019
This year’s ASH saw a plethora of presentations on BCMA-targeting drugs, but analysts at Jefferies say Bluebird Bio’s CAR-T therapy bb2121 “is still leading the pack.”....
European approval for Takeda's Alunbrig in ALK+ advanced non-small cell lung cancer pharmafile
November 28, 2018
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive (ALK+) advanced non-small...